Clinical and Molecular Characteristics of 60 Patients With Human Immunodeficiency Virus-Negative Castleman Disease.
Castleman disease
classifications
mTOR pathway
prognosis
thrombocytopenia
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
18
03
2022
accepted:
19
04
2022
entrez:
3
6
2022
pubmed:
4
6
2022
medline:
7
6
2022
Statut:
epublish
Résumé
Castleman disease (CD) is a rare lymphoproliferative disorder. The mechanistic target of rapamycin (mTOR) pathway is a key regulator of various cellular functions, which may be related with the potential mechanisms of CD occurrence. We retrospectively collected the clinical information of 60 CD patients diagnosed in the First Affiliated Hospital of Zhengzhou University. And FFPE biopsy specimens were collected from 31 patients (12 unicentric CD patients and 19 multicentric CD patients) to detect the mTOR pathway protein expression. We are the first to demonstrate that thrombocytopenia and hypoalbuminemia are independent poor prognostic factors for CD. Moreover, mTOR activation was higher in CD compared to reactive lymphoid hyperplasia (used as a control group). This study offers some elucidation for the management and treatment of CD patients.
Identifiants
pubmed: 35655778
doi: 10.3389/fimmu.2022.899073
pmc: PMC9152317
doi:
Substances chimiques
TOR Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
899073Informations de copyright
Copyright © 2022 Qian, Ding, Hou, Wang, Zhang, Zhang, Dong, Zhu, Wang, Li and Zhang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Cancer. 2010 May;46(7):1223-31
pubmed: 20335016
Blood. 2017 Mar 23;129(12):1658-1668
pubmed: 28100459
Front Immunol. 2022 Feb 10;13:827461
pubmed: 35222410
Clin Nucl Med. 2013 May;38(5):339-42
pubmed: 23429387
Cancer. 1999 Feb 1;85(3):706-17
pubmed: 10091744
Sci Rep. 2016 Mar 31;6:23831
pubmed: 27029894
J Cardiothorac Surg. 2009 Jul 09;4:31
pubmed: 19589162
J Cancer Res Clin Oncol. 2018 Jul;144(7):1265-1277
pubmed: 29736622
Blood. 2020 May 7;135(19):1673-1684
pubmed: 32206779
Lancet Haematol. 2016 Apr;3(4):e163-75
pubmed: 27063975
Blood Adv. 2020 Dec 8;4(23):6039-6050
pubmed: 33284946
Lancet Oncol. 2014 Aug;15(9):966-74
pubmed: 25042199
Leuk Lymphoma. 2019 Dec;60(14):3442-3448
pubmed: 31305183
Br J Haematol. 2018 Jan;180(2):206-216
pubmed: 29143319
Blood. 2015 Oct 29;126(18):2163
pubmed: 28448254
Leukemia. 2019 Apr;33(4):1035-1038
pubmed: 30607019
Am J Hematol. 2019 Jul;94(7):812-827
pubmed: 31012139
J Int Med Res. 2012;40(4):1580-8
pubmed: 22971511
Leuk Lymphoma. 2021 Dec;62(12):3031-3034
pubmed: 34159888
J Blood Med. 2018 Jan 22;9:15-23
pubmed: 29403325
Am J Hematol. 2018 Feb;93(2):296-305
pubmed: 29314206
Am J Hematol. 2012 Nov;87(11):997-1002
pubmed: 22791417
Br J Haematol. 2019 Jul;186(2):269-273
pubmed: 31016730
Br J Haematol. 2015 Jun;169(6):834-42
pubmed: 25824806
Oncologist. 2011;16(4):497-511
pubmed: 21441298
Blood. 2018 Nov 15;132(20):2115-2124
pubmed: 30181172
Eur J Nucl Med Mol Imaging. 2009 Apr;36(4):648-52
pubmed: 19050873
Blood. 2018 Nov 15;132(20):2109-2110
pubmed: 30442745
Nat Med. 2013 Oct;19(10):1193
pubmed: 24100967
Ann Surg. 1958 Mar;147(3):409-13
pubmed: 13509590
Adv Respir Med. 2018;86(1):36-43
pubmed: 29490420